Zhejiang pharma maker specializing in central-nervous-system generics such as sedatives and antidepressants, plus APIs.
Zhejiang pharma maker specializing in central-nervous-system generics such as sedatives and antidepressants, plus APIs.
Sells generic drugs mainly to hospitals, where volume is won by bidding in government-run purchasing programmes in which lower bids win larger orders, so scale and cost control matter more than pricing power. Central-nervous-system drugs carry the range, and active ingredients sold to other drugmakers add a smaller business.
In one line: A Chinese generics maker focused on CNS drugs.
Moat: none (scale). Generic manufacturer competing on tender price rather than proprietary products.
Headquarters: Shaoxing, Zhejiang, China · Employees: 3,732
Size Zhejiang Jingxin Pharmaceutical (002020.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.39B, the 1621st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.48 on 18 Nov 2026.
Performance Over six months the shares fell 19.4%, against -14.6% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +12.5%); the operating margin is 18.6% (peer median 10.9%).
Valuation It trades at 12.1× forward earnings against a peer median of 23.2× (4th cheapest of 10).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -14 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.06B | CN¥4.05B | CN¥4.14B | CN¥3.98B | CN¥3.76B |
| Revenue growth | — | -2% | +4% | +6% | — |
| Gross profit | CN¥2.22B | CN¥1.94B | CN¥1.97B | CN¥1.93B | CN¥1.90B |
| EBITDA | n/a | CN¥1.06B | CN¥1.02B | CN¥801M | CN¥818M |
| Net income | CN¥709M | CN¥758M | CN¥712M | CN¥619M | CN¥662M |
| Free cash flow | CN¥810M | CN¥606M | CN¥538M | CN¥305M | CN¥459M |
| Capital expenditure | CN¥196M | CN¥203M | CN¥251M | CN¥520M | CN¥516M |
| Total debt | CN¥524M | CN¥484M | CN¥603M | CN¥652M | CN¥640M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Jingxin Pharmaceutical 002020.SZ | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% |
| Livzon Pharmaceutical 000513.SZ | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002020.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -0.9% | -2.8% | 8th highest of 20 |
| 6-month return | -19.4% | -14.6% | 8th lowest of 20 |
| Distance from 52-week high | -47.0% | -40.0% | 9th lowest of 20 |
| Revenue growth (TTM) | +1.5% | +12.5% | 6th lowest of 18 |
| Operating margin | 18.6% | 10.9% | 4th highest of 18 |
| Forward P/E | 12.1× | 23.2× | 4th cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | -9.6% | 7.1% | 3rd least demanding of 9 |
| Growth delivered (Del g) | +4.6% | +16.6% | 2nd lowest of 9 |
| Hurdle (Req g minus delivered) | -14.1 pp | -13.4 pp | 5th least demanding of 9 |
| ROIC minus cost of capital | +8.5 pp | -1.8 pp | 3rd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Phibro Animal Health PAHC | United States | $1.44B | +5% | +10% | 13% | 9.9× | -6.4% | +12.7% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Xiamen Kingdomway 002626.SZ | China | $1.45B | -3% | -3% | 11% | 27.2× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.48B | +27% | +17% | 18% | 58.9× | 36.3% | +16.6% |
| LigaChem Biosciences 141080.KS | South Korea | $1.48B | -72% | -55% | -324% | n/a | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |